Corcept Therapeutics | CORT - Sales Revenues


Corcept Therapeutics reported $202.12M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
ANI Pharmaceuticals USD 247.06M 19.25M Dec/2025
Ardelyx USD 125.21M 14.89M Dec/2025
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 90.37M 7.65M Sep/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Canopy Growth CAD 66.68M 5.45M Sep/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
J&J USD 24.6B 610M Dec/2025
Knight Therapeutics CAD 121.55M 14.19M Sep/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Merck USD 16.4B 880M Dec/2025
Nektar Therapeutics USD 24.12M 635K Sep/2024
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pacira USD 196.87M 17.35M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Supernus Pharmaceuticals USD 211.6M 19.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025